Biotechnology venture capital investor SR One, a spinout from GlaxoSmithKline (GSK), has announced the final close of its debut fund on its hard-cap of $500m.
Health technology firm has made five deals from the fund and expects to back 10 companies in total
Providence originally acquired the education software provider in an SBO from TPG Capital
Inflexion accrues a 53% IRR from the sale of the network components manufacturer
The Clearwater International Multiples Heatmap reveals that average entry multiples broke new records in Q3, on the back of a still-buoyant M&A market